1 Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, California, USA.
2 Department of Radiation Oncology, Stanford Cancer Center, Stanford University, Stanford, California, USA.
Otolaryngol Head Neck Surg. 2018 Jun;158(6):1051-1056. doi: 10.1177/0194599817751679. Epub 2018 Jan 9.
Objective The National Cancer Center Network recommends starting radiation therapy within 6 weeks after surgery for oral cavity squamous cell carcinoma (OCSCC), but there is limited evidence of the importance of the total time from surgery to completion of radiation therapy (package time). We set out to determine if there was an association between package time and survival in OCSCC and to evaluate the impact of treatment location on outcomes. Study Design Retrospective cohort study. Setting Tertiary academic medical center. Subjects and Methods We reviewed the records of patients with OCSCC who completed postoperative radiation therapy at an academic medical center from 2008 to 2016. The primary endpoints were overall survival and recurrence-free survival. Statistical analysis included χ tests and Cox proportional hazards regressions. Results We identified 132 patients with an average package time of 12.6 weeks. On multivariate analysis, package time >11 weeks was independently associated with decreased overall survival (hazard ratio, 6.68; 95% CI, 1.42-31.44) and recurrence-free survival (hazard ratio, 2.94; 95% CI, 1.20-7.18). Patients who received radiation therapy at outside facilities were more likely to have treatment delays (90.2% vs 62.9%, P = .001). Conclusions Prolonged package times are associated with decreased overall and recurrence-free survival among patients with OCSCC. Patients who received radiation therapy at outside facilities are more likely to have prolonged package times.
美国国家癌症中心网络建议口腔鳞状细胞癌(OCSCC)患者在手术后 6 周内开始放射治疗,但关于手术到放射治疗完成的总时间(治疗套餐时间)的重要性的证据有限。我们旨在确定 OCSCC 患者的治疗套餐时间与生存之间是否存在关联,并评估治疗地点对结果的影响。
回顾性队列研究。
三级学术医疗中心。
我们回顾了 2008 年至 2016 年在学术医疗中心完成术后放射治疗的 OCSCC 患者的记录。主要终点是总生存率和无复发生存率。统计分析包括 χ 检验和 Cox 比例风险回归。
我们确定了 132 例平均治疗套餐时间为 12.6 周的患者。多变量分析显示,治疗套餐时间>11 周与总生存率(风险比,6.68;95%置信区间,1.42-31.44)和无复发生存率(风险比,2.94;95%置信区间,1.20-7.18)降低独立相关。在外部设施接受放射治疗的患者更有可能出现治疗延迟(90.2%比 62.9%,P =.001)。
OCSCC 患者的治疗套餐时间延长与总生存率和无复发生存率降低有关。在外部设施接受放射治疗的患者更有可能出现治疗套餐时间延长。